Baird Financial Group Inc. reduced its stake in Elanco Animal Health Incorporated (NYSE:ELAN – Get Rating) by 1.4% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 41,564 shares of the company’s stock after selling 592 shares during the quarter. Baird Financial Group Inc.’s holdings in Elanco Animal Health were worth $1,180,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of ELAN. Bank Julius Baer & Co. Ltd Zurich boosted its holdings in Elanco Animal Health by 11.2% in the 3rd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 170,942 shares of the company’s stock valued at $5,451,000 after purchasing an additional 17,267 shares during the period. Dendur Capital LP raised its holdings in shares of Elanco Animal Health by 6.3% in the 3rd quarter. Dendur Capital LP now owns 3,367,829 shares of the company’s stock worth $107,400,000 after buying an additional 200,000 shares in the last quarter. New York State Common Retirement Fund boosted its stake in shares of Elanco Animal Health by 11.0% in the 4th quarter. New York State Common Retirement Fund now owns 760,061 shares of the company’s stock valued at $21,571,000 after purchasing an additional 75,573 shares in the last quarter. Resonant Capital Advisors LLC grew its holdings in shares of Elanco Animal Health by 9.4% in the 4th quarter. Resonant Capital Advisors LLC now owns 13,680 shares of the company’s stock worth $388,000 after purchasing an additional 1,174 shares during the last quarter. Finally, Bennicas & Associates Inc. increased its position in shares of Elanco Animal Health by 3.4% during the 4th quarter. Bennicas & Associates Inc. now owns 16,306 shares of the company’s stock worth $463,000 after purchasing an additional 536 shares in the last quarter.
ELAN opened at $22.27 on Friday. The stock’s fifty day simple moving average is $25.69 and its 200 day simple moving average is $27.55. Elanco Animal Health Incorporated has a 1-year low of $20.51 and a 1-year high of $37.49. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.16 and a current ratio of 2.44.
A number of equities research analysts recently weighed in on ELAN shares. Barclays boosted their price target on shares of Elanco Animal Health from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Monday, February 28th. Zacks Investment Research downgraded Elanco Animal Health from a “hold” rating to a “sell” rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Elanco Animal Health presently has an average rating of “Hold” and an average price target of $38.43.
In other Elanco Animal Health news, Director R David Hoover acquired 5,000 shares of Elanco Animal Health stock in a transaction that occurred on Tuesday, March 1st. The shares were bought at an average price of $28.66 per share, with a total value of $143,300.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director John P. Bilbrey acquired 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 11th. The stock was bought at an average price of $22.03 per share, with a total value of $220,300.00. Following the completion of the acquisition, the director now directly owns 34,222 shares of the company’s stock, valued at $753,910.66. The disclosure for this purchase can be found here. 6.40% of the stock is currently owned by company insiders.
Elanco Animal Health Company Profile (Get Rating)
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
- Get a free copy of the StockNews.com research report on Elanco Animal Health (ELAN)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.